Drug resistance confounding prion therapeutics
نویسندگان
چکیده
منابع مشابه
Drug resistance confounding prion therapeutics.
There is not a single pharmaceutical that halts or even slows any neurodegenerative disease. Mounting evidence shows that prions cause many neurodegenerative diseases, and arguably, scrapie and Creutzfeldt-Jakob disease prions represent the best therapeutic targets. We report here that the previously identified 2-aminothiazoles IND24 and IND81 doubled the survival times of scrapie-infected, wil...
متن کاملThe prion dilemma confounding science educators
In this paper, the issue of the prion hypothesis, a simmering controversy within the scientific community, is addressed. We inquire into the appropriateness of the use of certain augmentations and rhetoric approaches used during scientific debates, as well as the aptness of unequivocal statements in textbooks that indicate "abnormal prions" as a primary cause of Transmissible Spongiform Encepha...
متن کاملDrug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics
1Department of Internal Medicine,The University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, USA 2Myeloma Institute for Research andTherapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA 3State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Unio...
متن کاملDeveloping Therapeutics for PrP Prion Diseases.
The prototypical PrP prion diseases are invariably fatal, and the search for agents to treat them spans more than 30 years, with limited success. However, in the last few years, the application of high-throughput screening, medicinal chemistry, and pharmacokinetic optimization has led to important advances. The PrP prion inoculation paradigm provides a robust assay for testing therapeutic effic...
متن کاملTherapeutics in Alzheimer's and prion diseases.
There is increasing recognition that numerous neurodegenerative conditions have the same underlying pathogenetic mechanism, namely a change in protein conformation, where the beta-sheet content is increased. In Alzheimer's disease, amyloid deposition in the form of neuritic plaques and congophilic angiopathy is driven by the conversion of normal soluble amyloid-beta peptide (sA beta) to A beta ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 2013
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.1317164110